Vicore Pharma AB (Vicore Pharma) engages in the development of novel pharmaceutical drugs that stimulate the AT2receptors, to address the unmet clinical needs in cardiovascular disease and other medical specialties. It conducts research and development into gastrointestinal and cardiovascular disorders. The company is focused on exploration of AT2receptor and commercialised the clinical potential in the different fields includes the consequences of hypertension and neurological disorders.In addition, the company is improving clinical outcome for cardiovascular diseases and focused to develop drugs for inflammation or neurodegeneration/damage are prominent aetiologies. The company designed, synthesised small non-peptide molecules to attractive new class of drugs. Vicore Pharma is headquartered in Goteborg, Sweden.